•Transmission:
faecal-oral
•Incubation:
2-6weeks
•High-risk
countries:
Eastern Europe, Africa, Asia, South America
Eastern Europe, Africa, Asia, South America
In
these regions almost every child comes into contact with the hepatitis A virus
before the age of 10
•
•The
proportion of symptomatic forms
and
complications increase with age
•Diagnosis: AST, ALT, IgM, IgG
•Prevention:
Hygienic measures
Immunization ( gives <3 months
immunity to those at risk)
•
Treatment: nospecific,
dietary food and long rest
•
•CHRONIC
LIVER DISEASE DOES NOT OCCUR!
ACUTE CHRONIC- 5-10%
(infection >6months)
•
•Every
year 1 to 2 million people die due to an infection by this virus
complications of chronic hepatitis
•
•More
than 350 million chronically infected worldwide
•Established
cause of chronic hepatitis and cirrhosis
•Human
carcinogen—cause of up to 80% of hepatocellular carcinomas
•More
than 600,000 deaths worldwide in 2002
•Hepadnavirus family (DNA)
•
•Numerous
antigenic components
•
•Humans
are only known host
•Fulminant
hepatitis
•Hospitalization
•Cirrhosis
•Hepato cellular carcinoma
•Death
•Transmission:
blood and body fluids, IV drug
abusers, sexual transmission
•Hepatitis
B virus primarily interferes with functions of the liver by replicating in
liver cells
Incubation period 6 weeks to 6 months (average 120 days)
•
•Nonspecific
prodrome
of fever, malaise, headache, myalgia
•At
least 50% of infections asymptomatic
•Any
sexual and intimate contact
•
Blood transfussion
•Infected
mother to newborn
•Kissing
•Needle
sharing
•Sharing
a toothbrush
Tattoo/body
piercing instruments
•Diagnosis:
HBsAg - 1-6 months after exposure
HBeAg
- 1-3 months after acute illness,
high infectivity
Anti-HBc
- past infection
Anti-HBs
- implies vaccination
HBsAg-positive
for at least 6 months
- hepatitis
B carriers (may
have chronic hepatitis B)
•Prevent
perinatal HBV transmission
•Routine
vaccination of all infants
•Vaccination
of children in high-risk groups
•Vaccination
of adolescents
•Vaccination
of adults in high-risk groups
•Prevention:
Vaccination
Avoid all Risk
factors
•Treatment:
Chronic-
PAGinterferon-2α
Antiviral drugs (lamivudine...)
THANKS YOU
No comments:
Post a Comment